# US 2023/0069345 A1 · Microbiome delivery platform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069345 A1
- Document ID: US20230069345A1
- Status: Published application
- Kind: A1
- Application number: 17/894,913
- Filed: 2022-08-24
- Published: 2023-03-02
- Earliest claimed: 2021-08-25
- Inventors: Augustine T. Zvinavashe
- Web page: https://patentgrep.com/patent/US20230069345A1

## CPC

- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/2063: {Proteins, e.g. gelatin}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/2833: {Organic macromolecular compounds}
- A61K 9/2873: {Proteins, e.g. gelatin}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 9/146: {with organic macromolecular compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure generally relates to preservation and delivery of a bioactive composition to a biological subject. In some embodiments, the bioactive composition include bioactives of at least one of microbes, cells, tissue, vaccines, probiotics, antibiotics, vitamins, or mRNA. Some embodiments include preserving the bioactive composition using vitrification of the bioactive composition in a vitrifying mixture of intrinsically disordered proteins and saccharides. The vitrified bioactive composition is configured to release the bioactive composition from the vitrifying mixture. Some embodiments include administering the vitrified bioactive composition to the biological subject, such that the administering includes applying the vitrified bioactive composition to a microbiome of the biological subject. Some embodiments may further include providing an enteric encapsulation of the vitrified bioactive composition that is configured to protect the vitrified bioactive composition from a first set of environmental conditions, but release the vitrified bioactive composition in a second set of environmental conditions.

## Claims

### Claim 1

A method of delivery of a bioactive composition to a biological subject, comprising:
providing a bioactive composition, the bioactive composition comprising bioactives of at least one of microbes, cells, tissue, vaccines, probiotics, antibiotics, vitamins, peptides, RNAi, or mRNA;
preserving the bioactive composition, the preserving comprising vitrification of the bioactive composition in a vitrifying mixture of intrinsically disordered proteins and saccharides to produce a vitrified bioactive composition, the vitrified bioactive composition is configured to release the bioactive composition from the vitrifying mixture; and
administering the vitrified bioactive composition to the biological subject, the administering comprises applying the vitrified bioactive composition to a microbiome of the biological subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
providing an enteric encapsulation of the vitrified bioactive composition, wherein:
the enteric encapsulation is configured to protect the vitrified bioactive composition from a first set of environmental conditions; and
the enteric encapsulation is configured to breakdown in a second set of environmental conditions, thereby releasing the vitrified bioactive composition.

### Claim 3 (depends on 2)

The method of claim 2, wherein the enteric encapsulation comprises:
an enteric polymer capsule in which the vitrified bioactive composition is placed; or
an enteric coating that entirely covers the vitrified bioactive composition.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
the intrinsically disordered proteins comprise at least one of a tardigrade intrinsically disordered protein, a silk fibroin, or tropoelastin; and
the saccharides are a disaccharide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the microbes comprise at least one of a fungus, a eubacterium, a eukaryotic organism, or an archaebacteria.

### Claim 6 (depends on 1)

The method of claim 1, wherein the bioactive composition is one of: anaerobic, aerobic, spore-forming, vegetative, native to a human microbiome, native to an animal microbiome, non-native to the human microbiome, non-native to the animal microbiome, native to a plant microbiome, non-native to the plant microbiome, an engineered version of the bioactive composition that is non-native to the human microbiome, or an engineered version of the bioactive composition that is non-native to the animal microbiome.

### Claim 7 (depends on 1)

The method of claim 1, wherein the bioactive composition is enhanced by an addition of metabolites and/or preservatives.

### Claim 8 (depends on 1)

The method of claim 1, wherein the biological subject is a human being.

### Claim 9 (depends on 8)

The method of claim 8, wherein the applying comprises applying the vitrified bioactive composition to at least one of skin, a vagina, a penis, a foot, or an armpit of the human being.

### Claim 10 (depends on 1)

The method of claim 1, wherein the applying comprises ingesting an enterically encapsulated vitrified bioactive composition in a form of at least one of an oral ingestible pill, an oral ingestible tablet, or a solution.

### Claim 11 (depends on 10)

The method of claim 10, wherein:
the enterically encapsulated vitrified bioactive composition is ingested in the form of an enterically encapsulated vitrified bioactive composition that enters a digestive track of the biological subject;
the enterically encapsulated vitrified bioactive composition passes through the digestive track intact until the enterically encapsulated vitrified bioactive composition experiences a pH of greater than about 6; and
the enterically encapsulated vitrified bioactive composition breaks down and releases the vitrified bioactive composition when it experiences the pH of greater than about 6; and
the vitrified bioactive composition releases the bioactive composition.

### Claim 12 (depends on 1)

The method of claim 1, wherein the vitrifying the bioactive composition comprises lowering the metabolism of the bioactives of the bioactive composition, thereby putting the bioactives in stasis.

### Claim 13 (depends on 1)

The method of claim 1, wherein the vitrifying the bioactive composition protects bioactive composition from dying due to exposure from oxygen.

### Claim 14 (depends on 10)

The method of claim 10, wherein;
the vitrified bioactive composition is released from the enterically encapsulated vitrified bioactive composition in a gut of the biological subject when the enterically encapsulated vitrified bioactive composition experiences a pH greater than a pH of about 6;
the vitrified bioactive composition is not released from the enterically encapsulated vitrified bioactive composition in a stomach of the biological subject, because a pH of the stomach is less than a pH of about 5.

### Claim 15 (depends on 14)

The method of claim 14, wherein:
the vitrified bioactive composition that is released in the gut of the biological subject adheres to intestinal mucus, rehydrates, resuscitates, and proliferates; and
the bioactive composition is released over a duration from the vitrified bioactive composition.

### Claim 16 (depends on 15)

The method of claim 15, wherein the bioactive composition that is released in the gut of the biological subject releases at least one of viable and healthy microbes, cells, tissue, vaccines, probiotics, antibiotics, or mRNA.

### Claim 17 (depends on 4)

The method of claim 4, wherein:
the silk fibroin is extracted from Bombyx Mori; and
the disaccharide is trehalose.

### Claim 18 (depends on 1)

The method of claim 1, wherein prebiotics are included in the bioactive composition to provide energy to nourish the bioactives.

### Claim 19 (depends on 1)

The method of claim 1, wherein:
the biological subject is a plant, a seed, or a soil;
the applying comprises spraying a solution containing particles and/or a powder of enterically encapsulated vitrified bioactive composition on the plant, seed, or soil.

### Claim 20

A composition for application to a microbiome of a biological subject, comprising:
a bioactive composition, the bioactive composition comprising bioactives of at least one of microbes, cells, tissue, vaccines, probiotics, antibiotics, vitamins, or mRNA; and
a vitrifying mixture, the vitrifying mixture comprising intrinsically disordered proteins and saccharides, wherein the bioactive composition is preserved in the vitrifying mixture to form a vitrified bioactive composition.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the composition further comprises:
an enteric encapsulant, the enteric encapsulant configured to encapsulate the vitrified bioactive composition to protect the vitrified bioactive composition from a first set of environmental conditions and to release the vitrified bioactive composition in a second set of environmental conditions.

### Claim 22 (depends on 20)

The composition of claim 20, wherein the bioactive is freeze dried in preparation for being preserved in the vitrifying mixture.

### Claim 23 (depends on 20)

The composition of claim 20, wherein the bioactive composition further comprises a probiotic and/or an antibiotic.

### Claim 24 (depends on 20)

The composition of claim 20, wherein the vitrified bioactive composition is incorporated in a skin care lotion.

### Claim 25 (depends on 20)

The composition of claim 20, wherein the vitrified bioactive composition is incorporated in a wound healing medication.

### Claim 26 (depends on 20)

The composition of claim 20, wherein:
the intrinsically disordered proteins are a silk fibroin; and
the saccharides are a disaccharide.

### Claim 27 (depends on 20)

The composition of claim 20, wherein the intrinsically disordered proteins comprise:
a naturally occurring protein; or
a synthetic polymer.

### Claim 28

A method of delivery of a bioactive composition to a biological subject, comprising:
providing a bioactive composition, the bioactive composition comprising at least one bioactive;
preserving the bioactive composition, the preserving comprising vitrification of the bioactive composition in a vitrifying mixture of intrinsically disordered proteins and saccharides to produce a vitrified bioactive composition, the vitrified bioactive composition is configured to release the bioactive composition from the vitrifying mixture;
providing an enteric encapsulation;
encapsulating the vitrified bioactive composition in the enteric encapsulation; and
administering the enterically encapsulated vitrified bioactive composition to the biological subject, the administering comprises applying the enterically encapsulated vitrified bioactive composition to a microbiome of the biological subject.

### Claim 29 (depends on 28)

The method of claim 28, wherein the enteric encapsulation comprises either:
encapsulating the vitrified bioactive composition in a capsule comprising an enteric polymer; or
a coating particles of vitrified bioactive composition with an enteric material.

### Claim 30 (depends on 28)

The method of claim 28, wherein the bioactives comprise at least one of microbes, cells, tissue, vaccines, probiotics, antibiotics, vitamins, or mRNA.

### Claim 31 (depends on 28)

The method of claim 28, wherein:
the intrinsically disordered proteins are a silk fibroin; and
the saccharides are a disaccharide.

### Claim 32

A method of preserving a bioactive composition, comprising:
forming a vitrifying solution, comprising:
providing a liquid,
adding an intrinsically disordered protein to the liquid;
adding a saccharide to the liquid;
mixing the intrinsically disordered protein and the saccharide in the liquid to form the vitrifying solution;
adding the bioactive composition to the vitrifying solution;
mixing the bioactive composition in the vitrifying solution; and
removing the liquid from the bioactive composition in the vitrifying solution.

### Claim 33 (depends on 32)

The method of claim 32, further comprising:
heating the bioactive composition in the vitrifying solution to a temperature of between 20 degrees Celsius and 125 degrees Celsius.

### Claim 34 (depends on 32)

The method of claim 32, further comprising:
cooling the bioactive composition in the vitrifying solution to a temperature of between 0 degrees Celsius and −80 degrees Celsius.

### Claim 34 (depends on 32)

The method of claim 32, wherein removing the liquid comprises at least one of air-drying, freeze-drying, vacuum drying, or heat-drying.

### Claim 35 (depends on 32)

The method of claim 32, wherein the liquid comprises water or an alcohol.
